183 related articles for article (PubMed ID: 35460355)
1. CT-based morphologic and radiomics features for the classification of MYCN gene amplification status in pediatric neuroblastoma.
Tan E; Merchant K; Kn BP; Cs A; Zhao JJ; Saffari SE; Tan PH; Tang PH
Childs Nerv Syst; 2022 Aug; 38(8):1487-1495. PubMed ID: 35460355
[TBL] [Abstract][Full Text] [Related]
2. Prediction of MYCN Gene Amplification in Pediatric Neuroblastomas: Development of a Deep Learning-Based Tool for Automatic Tumor Segmentation and Comparative Analysis of Computed Tomography-Based Radiomics Features Harmonization.
Yeow LY; Teh YX; Lu X; Srinivasa AC; Tan E; Tan TSE; Tang PH; Kn BP
J Comput Assist Tomogr; 2023 Sep-Oct 01; 47(5):786-795. PubMed ID: 37707410
[TBL] [Abstract][Full Text] [Related]
3. Radiogenomics of neuroblastoma in pediatric patients: CT-based radiomics signature in predicting MYCN amplification.
Wu H; Wu C; Zheng H; Wang L; Guan W; Duan S; Wang D
Eur Radiol; 2021 May; 31(5):3080-3089. PubMed ID: 33118047
[TBL] [Abstract][Full Text] [Related]
4. Radiogenomics prediction for MYCN amplification in neuroblastoma: A hypothesis generating study.
Di Giannatale A; Di Paolo PL; Curione D; Lenkowicz J; Napolitano A; Secinaro A; Tomà P; Locatelli F; Castellano A; Boldrini L
Pediatr Blood Cancer; 2021 Sep; 68(9):e29110. PubMed ID: 34003574
[TBL] [Abstract][Full Text] [Related]
5. Role of MRI radiomics for the prediction of MYCN amplification in neuroblastomas.
Ghosh A; Yekeler E; Teixeira SR; Dalal D; States L
Eur Radiol; 2023 Oct; 33(10):6726-6735. PubMed ID: 37178203
[TBL] [Abstract][Full Text] [Related]
6. CT-Based Radiomics Signature With Machine Learning Predicts MYCN Amplification in Pediatric Abdominal Neuroblastoma.
Chen X; Wang H; Huang K; Liu H; Ding H; Zhang L; Zhang T; Yu W; He L
Front Oncol; 2021; 11():687884. PubMed ID: 34109133
[TBL] [Abstract][Full Text] [Related]
7.
Qian LD; Zhou ZA; Li SQ; Liu J; Zhang SX; Ren JL; Wang W; Yang J
Quant Imaging Med Surg; 2024 Apr; 14(4):3131-3145. PubMed ID: 38617169
[TBL] [Abstract][Full Text] [Related]
8. Incorporating Radiomics into Machine Learning Models to Predict Outcomes of Neuroblastoma.
Liu G; Poon M; Zapala MA; Temple WC; Vo KT; Matthay KK; Mitra D; Seo Y
J Digit Imaging; 2022 Jun; 35(3):605-612. PubMed ID: 35237892
[TBL] [Abstract][Full Text] [Related]
9. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
[TBL] [Abstract][Full Text] [Related]
10. Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy.
Yanishevski D; McCarville MB; Doubrovin M; Spiegl HR; Zhao X; Lu Z; Federico SM; Furman WL; Murphy AJ; Davidoff AM
J Pediatr Surg; 2020 Jan; 55(1):130-134. PubMed ID: 31685267
[TBL] [Abstract][Full Text] [Related]
11. Predicting amplification of
Giwa A; Rossouw SC; Fatai A; Gamieldien J; Christoffels A; Bendou H
Future Oncol; 2021 Dec; 17(34):4769-4783. PubMed ID: 34751044
[TBL] [Abstract][Full Text] [Related]
12. A Random Forest-based Classifier for MYCN Status Prediction in Neuroblastoma using CT Images.
Pereira T; Silva F; Claro P; Carvalho DC; Dias SC; Torrao H; Oliveira HP
Annu Int Conf IEEE Eng Med Biol Soc; 2022 Jul; 2022():3854-3857. PubMed ID: 36086471
[TBL] [Abstract][Full Text] [Related]
13. Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Campbell K; Naranjo A; Hibbitts E; Gastier-Foster JM; Bagatell R; Irwin MS; Shimada H; Hogarty M; Park JR; DuBois SG
Eur J Cancer; 2020 Jul; 133():112-119. PubMed ID: 32492633
[TBL] [Abstract][Full Text] [Related]
14. Whole-tumour apparent diffusion coefficient (ADC) histogram analysis to identify MYCN-amplification in neuroblastomas: preliminary results.
Ghosh A; Yekeler E; Dalal D; Holroyd A; States L
Eur Radiol; 2022 Dec; 32(12):8453-8462. PubMed ID: 35437614
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of MYCN related genes in pediatric neuroblastoma: a study based on TARGET and GEO datasets.
Wang H; Wang X; Xu L; Zhang J; Cao H
BMC Pediatr; 2020 Jun; 20(1):314. PubMed ID: 32593299
[TBL] [Abstract][Full Text] [Related]
16. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
Hallett RM; Seong AB; Kaplan DR; Irwin MS
Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
Marrano P; Irwin MS; Thorner PS
Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Campbell K; Shyr D; Bagatell R; Fischer M; Nakagawara A; Nieto AC; Brodeur GM; Matthay KK; London WB; DuBois SG
Pediatr Blood Cancer; 2019 Aug; 66(8):e27819. PubMed ID: 31115156
[TBL] [Abstract][Full Text] [Related]
19. Clinical parameters combined with radiomics features of PET/CT can predict recurrence in patients with high-risk pediatric neuroblastoma.
Feng L; Qian L; Yang S; Ren Q; Zhang S; Qin H; Wang W; Wang C; Zhang H; Yang J
BMC Med Imaging; 2022 May; 22(1):102. PubMed ID: 35643445
[TBL] [Abstract][Full Text] [Related]
20. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
